A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Imilecleucel-T (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms Abili-T
- Sponsors EMD Serono; Opexa Therapeutics
- 09 Jan 2017 Status changed from active, no longer recruiting to completed.
- 16 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
- 16 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2016.